- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 521248, 10 pages
Application of Adoptive T-Cell Therapy Using Tumor Antigen-Specific T-Cell Receptor Gene Transfer for the Treatment of Human Leukemia
1Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan
2Department of Cell Growth and Cancer Regulation, Ehime University Proteomedicine Research Center, Shitsukawa, Toon, Ehime 791-0295, Japan
Received 11 December 2009; Accepted 13 February 2010
Academic Editor: Kim Klonowski
Copyright © 2010 Toshiki Ochi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. A. Rosenberg and M. E. Dudley, “Adoptive cell therapy for the treatment of patients with metastatic melanoma,” Current Opinion in Immunology, vol. 21, no. 2, pp. 233–240, 2009.
- L. A. Johnson, R. A. Morgan, M. E. Dudley, et al., “Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen,” Blood, vol. 114, no. 3, pp. 535–546, 2009.
- R. A. Morgan, M. E. Dudley, J. R. Wunderlich, et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006.
- J. D. Abad, C. Wrzensinski, W. Overwijk, et al., “T-cell receptor gene therapy of established tumors in a murine melanoma model,” Journal of Immunotherapy, vol. 31, no. 1, pp. 1–6, 2008.
- M. A. De Witte, A. Jorritsma, A. Kaiser, et al., “Requirements for effective antitumor responses of TCR transduced T cells,” Journal of Immunology, vol. 181, no. 7, pp. 5128–5136, 2008.
- M. H. Qazilbash, E. D. Wieder, P. F. Thall, et al., “PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia,” Blood, vol. 110, p. 90a, 2007, abstract no. 283.
- U. Keilholz, A. Letsch, A. Busse, et al., “A clinical and immunological phase II trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS,” Blood, vol. 113, no. 26, pp. 6541–6548, 2009.
- S.-A. Xue, L. Gao, D. Hart, et al., “Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells,” Blood, vol. 106, no. 9, pp. 3062–3067, 2005.
- B. Mommaas, A. G. S. van Halteren, J. Pool, et al., “Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer,” Haematologica, vol. 90, no. 10, pp. 1415–1421, 2005.
- M. H. M. Heemskerk, M. Hoogeboom, R. A. de Paus, et al., “Redirection of antileukemic reactivity of peripheral T lymphocytes using genetransfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region,” Blood, vol. 102, no. 10, pp. 3530–3540, 2003.
- T. Tsuji, M. Yasukawa, J. Matsuzaki, et al., “Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes,” Blood, vol. 106, no. 2, pp. 470–476, 2005.
- P. L. Weiden, N. Flournoy, and E. D. Thomas, “Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts,” New England Journal of Medicine, vol. 300, no. 19, pp. 1068–1073, 1979.
- P. L. Weiden, K. M. Sullivan, N. Flournoy, R. Storb, and E. D. Thomas, “Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation,” New England Journal of Medicine, vol. 304, no. 25, pp. 1529–1533, 1981.
- F. Michor, T. P. Hughes, Y. Iwasa, et al., “Dynamics of chronic myeloid leukaemia,” Nature, vol. 435, no. 7046, pp. 1267–1270, 2005.
- N. P. Shah, B. J. Skaggs, S. Branford, et al., “Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2562–2569, 2007.
- J. J. Molldrem, P. P. Lee, C. Wang, et al., “Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia,” Nature Medicine, vol. 6, no. 9, pp. 1018–1023, 2000.
- K. Rezvani, M. Grube, J. M. Brenchley, et al., “Functional leukemia-associated antigen-specific memory T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation,” Blood, vol. 102, no. 8, pp. 2892–2900, 2003.
- Y. Oka, A. Tsuboi, T. Taguchi, et al., “Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 38, pp. 13885–13890, 2004.
- S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004.
- M. E. Dudley, J. R. Wunderlich, P. F. Robbins, et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002.
- C. Yee, J. A. Thompson, D. Byrd, et al., “Adoptive T cell therapy using antigen-specific T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002.
- N. N. Hunder, H. Wallen, J. Cao, et al., “Treatment of metastatic melanoma with autologous T cells against NY-ESO-1,” New England Journal of Medicine, vol. 358, no. 25, pp. 2698–2703, 2008.
- E. Marijt, A. Wafelman, M. van der Hoorn, et al., “Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation,” Haematologica, vol. 92, no. 1, pp. 72–80, 2007.
- H.-J. Kolb, “Graft-versus-leukemia effects of transplantation and donor lymphocytes,” Blood, vol. 112, no. 12, pp. 4371–4383, 2008.
- J. H. F. Falkenburg, A. R. Wafelman, P. Joosten, et al., “Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes,” Blood, vol. 94, no. 4, pp. 1201–1208, 1999.
- S.-A. Xue, L. Gao, S. Thomas, et al., “Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice,” Haematologica, vol. 95, no. 1, pp. 126–134, 2010.
- S. Thomas, S.-A. Xue, M. Cesco-Gaspere, et al., “Targeting the wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells,” Journal of Immunology, vol. 179, no. 9, pp. 5803–5810, 2007.
- S. Okamoto, J. Mineno, H. Ikeda, et al., “Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR,” Cancer Research, vol. 69, no. 23, pp. 9003–9011, 2009.
- M. H. M. Heemskerk, M. Hoogeboom, R. Hagedoorn, M. G. D. Kester, R. Willemze, and J. H. F. Falkenburg, “Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 885–894, 2004.
- Z. Dembic, W. Haas, and S. Weiss, “Transfer of specificity by murine and T-cell receptor genes,” Nature, vol. 320, no. 6059, pp. 232–238, 1986.
- T. M. Clay, M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura, “Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity,” Journal of Immunology, vol. 163, no. 1, pp. 507–513, 1999.
- R. A. Willemsen, M. E. M. Weijtens, C. Ronteltap, et al., “Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR,” Gene Therapy, vol. 7, no. 16, pp. 1369–1377, 2000.
- A. Hiasa, M. Hirayama, H. Nishikawa, et al., “Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) genes transduced to T cells,” Gene Therapy, vol. 15, no. 9, pp. 695–699, 2008.
- R. A. Morgan, M. E. Dudley, Y. Y. L. Yu, et al., “High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens,” Journal of Immunology, vol. 171, no. 6, pp. 3287–3295, 2003.
- Y. Zhao, Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan, “Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines,” Journal of Immunology, vol. 174, no. 7, pp. 4415–4423, 2005.
- Y. Date, A. Kimura, H. Kato, and T. Sasazuki, “DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese,” Tissue Antigens, vol. 47, no. 2, pp. 93–101, 1996.
- P. Krausa, M. Brywka III, U. Savage, et al., “Genetic polymorphism within HLA-: significant allelic variation revealed in different populations,” Tissue Antigens, vol. 45, no. 4, pp. 223–231, 1995.
- H. Ohminami, M. Yasukawa, and S. Fujita, “HLA class I-restricted lysis of leukemia cells by a cytotoxic T- lymphocyte clone specific for WT1 peptide,” Blood, vol. 95, no. 1, pp. 286–293, 2000.
- M. Yasukawa, H. Fujiwara, T. Ochi, et al., “Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome,” American Journal of Hematology, vol. 84, no. 5, pp. 314–315, 2009.
- L. Duval, H. Schmidt, K. Kaltoft, et al., “Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma,” Clinical Cancer Research, vol. 12, no. 4, pp. 1229–1236, 2006.
- M. E. Call and K. W. Wucherpfennig, “The T cell receptor: critical role of the membrane environment in receptor assembly and function,” Annual Review of Immunology, vol. 23, pp. 101–125, 2005.
- M. H. M. Heemskerk, R. S. Hagedoorn, M. A. W. G. van der Hoorn, et al., “Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex,” Blood, vol. 109, no. 1, pp. 235–243, 2007.
- C. J. Cohen, Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan, “Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability,” Cancer Research, vol. 66, no. 17, pp. 8878–8886, 2006.
- C. J. Cohen, Y. F. Li, M. El-Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan, “Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond,” Cancer Research, vol. 67, no. 8, pp. 3898–3903, 2007.
- J. Kuball, M. L. Dossett, M. Wolfl, et al., “Facilitating matched pairing and expression of TCR chains introduced into human T cells,” Blood, vol. 109, no. 6, pp. 2331–2338, 2007.
- Z. Sebestyen, E. Schooten, T. Sals, et al., “Human TCR that incorporate CD3 induce highly preferred pairing between TCR and chains following gene transfer,” Journal of Immunology, vol. 180, no. 11, pp. 7736–7746, 2008.
- K. B. J. Scholten, D. Kramer, E. W. M. Kueter, et al., “Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells,” Clinical Immunology, vol. 119, no. 2, pp. 135–145, 2006.
- L. T. van der Veken, R. S. Hagedoorn, M. M. van Loenen, R. Willemze, J. H. F. Falkenburg, and M. H. M. Heemskerk, “ T-cell receptor engineered T cells mediate effective antileukemic reactivity,” Cancer Research, vol. 66, no. 6, pp. 3331–3337, 2006.
- A. Hiasa, H. Nishikawa, M. Hirayama, et al., “Rapid TCR-mediated responses in T cells transduced with cancer-specific TCR genes,” Gene Therapy, vol. 16, no. 5, pp. 620–628, 2009.
- W. R. Burns, Z. Zheng, S. A. Rosenberg, and R. A. Morgan, “Lack of specific -retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation,” Blood, vol. 114, no. 14, pp. 2888–2899, 2009.
- M. A. Pule, B. Savoldo, G. D. Myers, et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008.
- C. Berger, M. C. Jensen, P. M. Lansdorp, M. Gough, C. Elliott, and S. R. Riddell, “Adoptive transfer of effector T cells derived from central memory cells establishes persistent T cell memory in primates,” Journal of Clinical Investigation, vol. 118, no. 1, pp. 294–305, 2008.
- C. S. Hinrichs, Z. A. Borman, L. Cassard, et al., “Adoptively transferred effector cells derived from naïve rather than central memory T cells mediate superior antitumor immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 41, pp. 17469–17474, 2009.
- A. U. van Lent, M. Nagasawa, M. M. van Loenen, et al., “Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors,” Journal of Immunology, vol. 179, no. 8, pp. 4959–4968, 2007.
- Y. Zhao, M. R. Parkhurst, Z. Zheng, et al., “Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via notch signaling,” Cancer Research, vol. 67, no. 6, pp. 2425–2429, 2007.
- C. Bonini, G. Ferrari, S. Verzeletti, et al., “HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia,” Science, vol. 276, no. 5319, pp. 1719–1724, 1997.
- F. Ciceri, C. Bonini, S. Marktel, et al., “Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation,” Blood, vol. 109, no. 11, pp. 4698–4707, 2007.
- F. Ciceri, C. Bonini, M. T. L. Stanghellini, et al., “Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study,” The Lancet Oncology, vol. 10, no. 5, pp. 489–500, 2009.
- A. Recchia, C. Bonini, Z. Magnani, et al., “Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1457–1462, 2006.
- N. Cartier, S. Hacein-Bey-Abina, C. C. Bartholomae, et al., “Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy,” Science, vol. 326, no. 5954, pp. 818–823, 2009.
- A. Aiuti, F. Cattaneo, S. Galimberti, et al., “Gene therapy for immunodeficiency due to adenosine deaminase deficiency,” New England Journal of Medicine, vol. 360, no. 5, pp. 447–458, 2009.
- A. Krishnan, J. A. Zaia, J. Rossi, et al., “First in human engraftment of anti-HIV lentiviral vector gene modified peripheral blood progenitor cells in the treatment of AIDS related lymphoma (ARL),” Blood, vol. 112, p. 818a, 2008, abstract no. 2348.
- M. L. Dossett, R. M. Teague, T. M. Schmitt, et al., “Adoptive immunotherapy of disseminated leukemia with TCR-transduced, T cells expressing a known endogenous TCR,” Molecular Therapy, vol. 17, no. 4, pp. 742–749, 2009.
- T. Ochi, H. Fujiwara, and M. Yasukawa, “Aurora-A kinase: a novel target both for cellular immunotherapy and molecular target therapy against human leukemia,” Expert Opinion on Therapeutic Targets, vol. 13, no. 12, pp. 1399–1410, 2009.
- T. Ochi, H. Fujiwara, K. Suemori, et al., “Aurora-A kinase: a novel target of cellular immunotherapy for leukemia,” Blood, vol. 113, no. 1, pp. 66–74, 2009.
- K. Nagai, H. Fujiwara, T. Ochi, et al., “Development of a novel anti-leukemia gene immunotherapy using Aurora-A kinase-specific T-cell receptor gene transfer,” Blood, vol. 114, p. 158a, 2009, abstract no. 375.
- J. Arai, M. Yasukawa, H. Ohminami, M. Kakimoto, A. Hasegawa, and S. Fujita, “Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes,” Blood, vol. 97, no. 9, pp. 2903–2907, 2001.